Protein expression and significance of VEGF, EGFR and MMP-9 in non-small cell lung carcinomas

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 6, 2011, Pages 1473-1476

  Jin, Yi ^a   Li, Jia Ping ^a   Tang, Lu Ying ^a   Chen, Jian Ning ^a   Feng, Zhi Ying ^a   Liu, Yong ^a   Zhou, Jing ^a   Shao, Chun Kui ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

EGFR; Immunohistochemistry; MMP 9; NSCLCs; VEGF

Indexed keywords

EID: 84863275932     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Berghmans T, Meert AP, Martin B, et al (2005). Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer. Eur Respir J, 25, 329-35.
2. Byers LA, Heymach JV (2007). Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small cell lung cancer. Clin Lung Cancer, 8, 79-85.
3. Chang SH, Kanasaki K, Gocheva V, et al (2009).VEGF-A induces angiogenesis by perturbing the cathepsin-cysteine protease inhibitor balance in venules, causing basement membrane degradation and mother vessel formation. Cancer Res, 69, 4537-44.
4. Di Cristofano A, Pesce B, Cordon-Cardo C, et al (1998). PTEN is essential for embryonic development and tumor suppression. Nat Genet, 19, 348-55.
5. Hofmann UB, Westphal JR, V Muijen, et al (2000). Matrix metalloproteinases in human melanoma. J Invest Dermatol, 115, 337-44.
6. Jemal A, Siegel R, Ward E, et al (2008). Cancer statistics 2008. CA Cancer J Clin, 58, 71-96.
7. Jeon YK, Sung SW, Chung JH, et al (2006). Clinicopathologic features and prognostic implications of epidermal growth factor receptor (EGFR) gene copy number and protein expression in non-small cell lung cancer. Lung Cancer, 54, 387-98.
8. Kojima H, Shijubo N, Yamada G, et al (2005). Clinical significance of vascular endothelial growth factor2C and vascular endothelial growth factor receptor 3 in patients with T1 lung adenocarcinoma. Cancer, 104, 1668-77.
9. Krause DS, Van Etten RA (2005). Tyrosine kinases as targets for cancer therapy. N Engl J Med, 353, 172-87.
10. Rami-Porta R, Crowley JJ, Goldstraw P (2009). The revised TNM staging system for lung cancer. Ann Thorac Cardiovasc Surg, 15, 4-9.
11. Safranek J, Pesta M, Holubec L, et al (2009). Expression of MMP-7, MMP-9, TMP-1 and TMP-2 mRNA in lung tissue of patients with non-small cell lung cancer(NSCLC) and benign pulmonary disease. Anticancer Res, 29, 2513-7.
12. Sinnamon MJ, Carter KJ, Fingleton B, et al (2008). Matrix metalloproteinase-9 contributes to intestinal tumourigenesis in the adenomatous polyposis coli multiple intestinal neoplasia mouse. Int J Exp Pathol, 89, 466-75.
13. Stefanoup D, Goussia AC, Arkoumani E, et al (2003). Expression of vascular endothelial growth factor and the adhesion molecule E-cadherin in non small cell lung cancer. Anti Cancer Res, 23, 4715-20.
14. Wellmann S, Taube T, Paal K, et al (2001). Specific reverse transcription-PCR quantification of vascular endothelial growth factor (VEGF) splice variants by LightCycler technology. Clin Chem, 47, 654-60.